Suchergebnisse - "Janjigian, Yelena Y"

PubPharm (6)

1

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

enthalten in: Cancer discovery | 2019

von Sanchez-Vega, F. | Hechtman, J. | Castel, P. | +36

CommentIn: Cancer Discov. 2019 Feb;9(2):166-168. - PMID 30737213

2

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition

enthalten in: Cancer discovery | 2018

von Harding, J. | Lowery, M. | Shih, A. | +29

3

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

enthalten in: Cancer discovery | 2018

von Janjigian, Y. | Sanchez-Vega, F. | Jonsson, P. | +37

CommentIn: Cancer Discov. 2018 Jan;8(1):14-16. - PMID 29311223

4

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

enthalten in: Cancer discovery | 2014

von Janjigian, Y. | Smit, E. | Groen, H. | +9

CommentIn: Cancer Discov. 2014 Sep;4(9):991-4. - PMID 25185188

5

Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase InhibitorResistant EGFR-Mutant Lung Cancer with and without T790M Mutations

enthalten in: Cancer discovery | 2014

von Janjigian, Y. | Smit, E. | Groen, H. | +9

6

HER2 amplification : a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

enthalten in: Cancer discovery | 2012

von Takezawa, K. | Pirazzoli, V. | Arcila, M. | +13

1
[1]